Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Claire Long

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

ABPI London offices

UK pharma slams new drug evaluation plans

ABPI and BIA oppose "arbitrary" proposal to impose £100,000 QALY limit on rare disease therapies

- PMLiVE

Merck settles PD-1 patent lawsuit with BMS and Ono

Agrees to pay $625m settlement plus royalties on sales of Keytruda until 2026

- PMLiVE

Decibel Therapeutics expands leadership team

John Keilty, Dr Troyen Brennan, Roger Brown and Dr George Scangos join

- PMLiVE

A rare talent

Shire’s Sebastian Stachowiak on dealing with change and working for a fit-for-purpose orphan drug environment

- PMLiVE

Narrative Health appoints research director

Lucy Oates brings experience from Merck and Cello Health

Pfizer invests in Swedish digital health firm

AMRA's technology transforms MRI images into precise fat and muscle measurements 

- PMLiVE

Celgene bid to push Revlimid beyond myeloma blocked again

Cancer treatment fails phase III trial in lymphoma

- PMLiVE

Anna Korving joins Hanover Health as chair

She most recently served as Publicis's executive VP, global business development

- PMLiVE

Is print the new vinyl?

The release of the National Medical Readership Survey prompts the inevitable discussion about the role of print vs. other channels in the marketing mix, when targeting GPs and HCPs generally...

- PMLiVE

FDA approves Synergy’s constipation drug Trulance

Set to launch by March this year, analysts say the CIC therapy could see sales of $450m by 2020

Bristol-Myers Squibb (BMS) building

BMS won’t seek quick okay for Opdivo combo in lung cancer

No longer intends to file for accelerated approval, pushing predicted approval date back to late 2018

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links